Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024
ATNM Stock | USD 1.28 0.02 1.54% |
About 61% of Actinium Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Actinium Pharmaceuticals suggests that many traders are alarmed. Actinium Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Actinium Pharmaceuticals. Many technical investors use Actinium Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Actinium |
Actinium Pharmaceuticals, Inc. , a leader in the development of Antibody Radiation Conjugates and other targeted radiotherapies, today highlighted recent regulatory and development updates for its Iomab-B, Actimab-A and Iomab-ACT ARC clinical programs as well as its financial results for the third quarter ended September 30, 2024. Iomab-B is a first in class CD45 targeted conditioning agent to enable bone marrow transplant and has been
Read at finance.yahoo.com
Actinium Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Actinium Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Actinium Pharmaceuticals Fundamental Analysis
We analyze Actinium Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Actinium Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Actinium Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Actinium Pharmaceuticals is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Actinium Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Actinium Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Actinium Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Actinium Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Actinium Pharmaceuticals Related Equities
RVPHW | Reviva Pharmaceuticals | 19.05 | ||||
RVPH | Reviva Pharmaceuticals | 5.56 | ||||
CGTX | Cognition Therapeutics | 3.69 | ||||
EXEL | Exelixis | 0.17 | ||||
TGTX | TG Therapeutics | 0.06 | ||||
FBIO | Fortress Biotech | 0.97 | ||||
VKTX | Viking Therapeutics | 1.04 | ||||
AXSM | Axsome Therapeutics | 1.09 | ||||
ANVS | Annovis Bio | 1.22 | ||||
ADAP | Adaptimmune Therapeutics | 1.30 | ||||
SAVA | Cassava Sciences | 1.38 | ||||
KOD | Kodiak Sciences | 1.48 | ||||
INKT | Mink Therapeutics | 1.52 | ||||
MDGL | Madrigal Pharmaceuticals | 1.99 | ||||
BTAI | BioXcel Therapeutics | 2.27 | ||||
MCRB | Seres Therapeutics | 3.23 | ||||
RIGL | Rigel Pharmaceuticals | 4.09 | ||||
SGMO | Sangamo Therapeutics | 4.64 | ||||
RNAZ | Transcode Therapeutics | 6.63 | ||||
AFMD | Affimed NV | 9.05 |
Check out Actinium Pharmaceuticals Hype Analysis, Actinium Pharmaceuticals Correlation and Actinium Pharmaceuticals Performance. To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Actinium Pharmaceuticals. If investors know Actinium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Actinium Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.39) | Revenue Per Share 0.003 | Quarterly Revenue Growth (1.00) | Return On Assets (0.31) | Return On Equity (0.88) |
The market value of Actinium Pharmaceuticals is measured differently than its book value, which is the value of Actinium that is recorded on the company's balance sheet. Investors also form their own opinion of Actinium Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Actinium Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Actinium Pharmaceuticals' market value can be influenced by many factors that don't directly affect Actinium Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Actinium Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Actinium Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Actinium Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.